Innovaderm continues use of Medrio’s EDC for dermatology trials
The specialty contract research organization (CRO) focused on dermatology, Innovaderm, has been a client of Medrio eClinical software for over 9 years, using its software in Phase I, IIa, and IIb studies.
The new agreement will see Innovaderm continue its use of Medrio’s eClinical software platforms, including: eSource, eConsent, and ePro, until 2023.
All of these eClinical software platforms are designed for the use in early-phase pharma clinical research, and include electronic data capture (EDC), which Innovaderm cited as part of the reason for continuing the partnership. “Organizations conducting all types of clinical trials use EDC to build study databases, store data electronically, detect and resolve data entry errors, run reports on their data, and more. The reason Medrio is particularly well-suited to early phase pharma trials has to do with simplicity and cost,” a company spokesperson told us.
The spokesperson explained that a platform with cloud-based EDC is a fit for early phase trials due to the needs of those studies, “Early phase trials typically use more straightforward study designs and often require mid-study changes to the database, and this goes hand-in-hand with Medrio enabling users to build studies on their own without any programming, which many other EDCs require, and easily make mid-study changes on the fly.”
Medrio’s eConsent was added to the company’s eClinical software platform in November 2018 as a way to provide clients with an electronic-consent application to accelerate clinical trial processes. The cloud-based platform enables sponsors and CROs to access consent forms instantly.
